drugset
drugset / Trial / NCT03594396

Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer

NCT03594396 ↗

Phase 1/2 Active not recruiting 54 enrolled Seoul National University Hospital AstraZeneca · collab
NaSingle-groupOpen-labelTreatment

Summary

Window of Opportunity Trial of Olaparib and Durvalumab (MEDI4736) before Standard Neoadjuvant Chemotherapy for Stage II/III Triple Negative or Low ER+ Breast Cancer

Timeline

Start
2018-06-29
Primary completion
2025-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Durvalumab Monoclonal antibody 1500 mg Intravenous
Subject Olaparib Small molecule 300 mg —

Indications

breast neoplasm